baber/WOPTO huggingface dataset:
Patent DE-69405054-D1 (DE)
Inventor: CAVAZZA CLAUDIO
IPC: A61K9/107
Filed: 1994-06-10
Granted: 1997-09-25
Abstract: The use is disclosed of esters of L-carnitine and acyl L-carnitines with hydroxyacids for producing pharmaceutical compositions suitable to be topically applied for treating dermatoses such as ichthyosis and psoriasis.
Patent DE-69410823-D1 (DE)
Inventor: LEGO FRANCOIS
IPC: F25B41/04
Filed: 1994-11-30
Granted: 1998-07-09
Abstract: PCT No. PCT/FR94/01401 Sec. 371 Date Jul. 2, 1996 Sec. 102(e) Date Jul. 2, 1996 PCT Filed Nov. 30, 1994 PCT Pub. No. WO95/15467 PCT Pub. Date Jun. 8, 1995A refrigerating exchanger (1) for a refrigeration facility such as a cold storage room or a refrigerated display case, including a refrigerant or heat-removing fluid circulating assembly (5) connected to a heat exchanging assembly (6) with a large surface area. The assemblies (5, 6) form an array of several layers (7) and several rows (8) in the form of a plurality of mutually similar parallel members (9) separated by spacers (10) for providing heat insulation and collecting defrosting runoff water. Each member (9) comprises at least one layer (7) as well as a respective inlet (11) and outlet (12) forming part of the circulating assembly (5). At least three members (9) of the array each have a refrigerating capacity that is a fraction of the overall standard rating of the exchanger (1) so that at any one time during the operation of the exchanger (1), at least one of the members (9) can be in defrosting mode while at least two of the members (9) are in refrigerating mode, the members (9) being in turn in defrosting mode and in refrigerating mode.
Patent DE-69415986-D1 (DE)
Inventor: MAMOU PATRICK
IPC: B65H23/04
Filed: 1994-08-05
Granted: 1999-02-25
Abstract: Against the internal side of the top portion of the back of a jacket (17), an identification article (4) is fixed, the latter comprising an identification label (34) which is fixed by means of a peripheral seam (19) traversing an edge (18) of the label (34), back-folded inwards. An influence device (20) is fixed, for example by gluing, against the reverse side of the label (34), inside the peripheral seam (19). The influence device (20) is then made normally inaccessible and unremovable due to the seam (19), without deterioration of the influence device by the seam. Furthermore, the influence device (20) is invisible. Utilization for simplifying the protection of garments against shoplifting.
Patent DE-69422777-D1 (DE)
Inventor: BRAEKEN JOSEF
IPC: C09D167/08
Filed: 1994-10-28
Granted: 2000-03-02
Abstract: High-solids air-drying or semi-drying alkyd paints essentially comprise, as binder, a conventional air-drying or semi-drying long-oil or medium-oil alkyd resin, and as reactive diluent an oligomer of polyol, polyisocyanate and unsaturated fatty acids. Use of the oligomer as reactive diluent is also claimed.
Patent DE-69425958-D1 (DE)
Inventor: LIMA-MARQUES LUIS
IPC: B41J2/015
Filed: 1994-02-11
Granted: 2000-10-26
Abstract: An apparatus and a method for the formation of droplets from meltable powdered solid or highly viscous materials such as inks (9) by reducing the viscosity (10, 14) of the material to a viscosity to enable droplet formation, providing the reduced viscosity ink to an ejection location (6), applying a constant or pulsed electrical potential (4) to the ejection location to form an electric field at the location and ejecting such droplets away from the ejection location by electrostatic means. Alternatively there may be constant electrical potential to form a constant electrostatic field at the ejection location and pulsed heating of the ejection location.
Patent DE-69425965-D1 (DE)
Inventor: VAN DER WEEGEN CLEMENS
IPC: A61B1/32
Filed: 1994-03-09
Granted: 2000-10-26
Abstract: PCT No. PCT/AU94/00111 Sec. 371 Date Nov. 30, 1995 Sec. 102(e) Date Nov. 30, 1995 PCT Filed Mar. 9, 1994 PCT Pub. No. WO94/21160 PCT Pub. Date Sep. 29, 1994A dilating speculum comprises a tubular body (8) adapted for connection at one end to an eye-piece and light source, a tubular probes (11) adapted to be inserted into the vagina or other body cavity and comprising an outer probe part (13) detachably secured to the tubular body (8) and an inner probe part (12) lodged within the bore of the outer part (13). An inflatable latex (15) sheath surrounds a length of the probe (11) and is sealed thereto at each end of that length. The seal at one end is effected by virtue of an end portion of the sheath (15) being sandwiched between the two probe parts (12, 13) and at the other end by a stretched elastic ring (35) encircling the probe (11) and sheath (15). A passage (24, 23, 25, 28, 29) through the body (8) and probe (11) allows the sheath (15) to be inflated between the seals.
Patent DE-69428276-D1 (DE)
Inventor: SCHOFIELD PAUL
IPC: A61P35/00
Filed: 1994-05-12
Granted: 2001-10-18
Abstract: PCT No. PCT/GB94/01030 Sec. 371 Date May 15, 1996 Sec. 102(e) Date May 15, 1996 PCT Filed May 12, 1994 PCT Pub. No. WO94/26300 PCT Pub. Date Nov. 24, 1994The invention relates to the use of IGF-II for the manufacture of a medicament for the treatment of tumours, and especially for the manufacture of a medicament for growth inhibition of melanoma cells and for the treatment of cutaneous melanomas. The medicament can be systemically or locally administered.
Patent DE-69433804-D1 (DE)
Inventor: WADA TOSHIHIDE
IPC: B41J25/34
Filed: 1994-01-12
Granted: 2004-07-01
Abstract: A recording apparatus for recording on a recording medium by use of a recording mechanism which travels along the recording medium comprises a carrier which enables the recording mechanism to travel along the recording medium, the carrier being capable of holding the recording mechanism detachably, and a carrier driving mechanism which enables the carrier to travel along the recording medium, the carrier driving mechanism prohibiting the movement of the carrier in an arbitrary position in the traveling area of the carrier. In this way, when the recording mechanism is attached to or detached from the carrier, the movement of the carrier is prohibited, thus making it possible to fix the carrier without any particular mechanism to suspend the movement of the carrier for a reliable and sound attachment or detachment of the recording mechanism to or from the carrier, and at the same time, to implement the miniaturization and lower cost of the apparatus. <IMAGE>
Patent DE-69434331-D1 (DE)
Inventor: PRESTON JOHN CLEMENT
IPC: E04G3/18
Filed: 1994-08-30
Granted: 2005-05-19
Abstract: A construction platform comprises a stationary support structure (300) comprising two guide beams (302) and four length adjustable struts (303) for securing the guide beams between adjacent floor of a building under construction, a landing deck (301) carried by the support structure and able to move to and fro between at least one inboard and at least one outboard position relative to the building, drive means to shift the landing deck between those positions, immobilising means to releasably lock the deck in said at least one outboard position, and safety barrier means (306, 7) extending about the periphery of the deck. In some embodiments the guide beams extend as cantilevers from the building and remain there when the deck is driven inboard. In other embodiments the deck extends as a self supporting cantilever in the outboard position and nothing projects from the building when the deck is inboard.
Patent DE-69504176-D1 (DE)
Inventor: GRANT PETER LEONARD
IPC: C12Q1/6818
Filed: 1995-01-10
Granted: 1998-09-24
Abstract: An assay for a target nucleotide sequence in a sample, comprises bringing into contact with the sample first and second nucleotide probes respectively labelled with first and second enzymes of a channelling pair, and wherein the probes hybridize at closely adjacent sites on the target sequence in such a way that the two enzyme labels are brought into juxtaposition, and introducing the materials (excluding substrate for the second enzyme that is formed by the first enzymic reaction) which allow the enzymic reactions to run, thereby generating a detectable signal in the presence of the target but not in its absence.
Patent DE-69505612-D1 (DE)
Inventor: ABATJOGLOU ANTHONY GEORGE
IPC: C07C45/50
Filed: 1995-08-18
Granted: 1998-12-03
Abstract: The present invention provides a hydroformylation process comprising: (1) forming a reaction mixture containing: (a) an olefinic compound, (b) hydrogen, (c) carbon monoxide, (d) a phosphite in which each phosphorus atom is bonded to three oxygen atoms and at least one such oxygen atom is bonded to a carbon atom of an aromatic ring that is adjacent to another carbon atom of said ring having a pendant monovalent group having a steric hindrance at least as great as the steric hindrance of the isopropyl group, (e) a catalytic amount of rhodium, and (f) a Group VIII metal (other than a rhodium) in an amount sufficient to reduce the rhodium-catalyzed decomposition of the phosphite during the hydroformylation process; and (2) maintaining the reaction mixture under conditions at which the olefinic compound reacts with the hydrogen and carbon monoxide to form an aldehyde.
Patent DE-69509223-D1 (DE)
Inventor: REITZ DAVID
IPC: C07D213/65
Filed: 1995-02-07
Granted: 1999-05-27
Abstract: A class of substituted spiro compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by formula (III), wherein n is a number selected from 0, 1 and 2; wherein R<6> is selected from hydrido and halo; wherein R<7> is selected from hydrido and halo; wherein R<8> is selected from hydrido, halo, lower alkyl, lower alkoxy, lower haloalkyl, lower haloalkoxy, and hydroxyl; wherein R<9> is selected from hydrido, halo, and lower alkyl; or wherein R<8> and R<9> together form methylenedioxy; and wherein R<11> is selected from lower alkyl and amino; or a pharmaceutically-acceptable salt thereof.
Patent DE-69520161-D1 (DE)
Inventor: GREBOW PETER E
IPC: A61P25/28
Filed: 1995-10-04
Granted: 2001-03-29
Abstract: The particle size of modafinil can have a significant effect on the potency and safety profile of the drug. The invention describes a process for the preparation of certain modafinil pharmaceutical compositions for use in altering the somnolent state of a mammal.
Patent DE-69520959-D1 (DE)
Inventor: MELIEF J
IPC: A61K38/04
Filed: 1995-03-21
Granted: 2001-06-21
Abstract: The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.
Patent DE-69521424-D1 (DE)
Inventor: KAWAI YOSHIO
IPC: A61K31/343
Filed: 1995-04-21
Granted: 2001-07-26
Abstract: PCT No. PCT/JP95/00787 Sec. 371 Date Oct. 25, 1996 Sec. 102(e) Date Oct. 25, 1996 PCT Filed Apr. 21, 1995 PCT Pub. No. WO95/29907 PCT Pub. Date Nov. 9, 1995   <IMAGE>  (I)  This invention relates to a novel heterocyclic compound represented by formula (I), wherein each symbol is as defined in the specification and a pharmaceutically acceptable salt thereof which are the inhibitors of bone resorption and bone metabolism, to processes for preparation thereof, to a pharmaceutical composition comprising the same and to a method for the treatment of diseases caused by abnormal bone metabolism in human being or an animal.
Patent DE-69522580-D1 (DE)
Inventor: LARSEN SCOTT D
IPC: C07C281/16
Filed: 1995-11-13
Granted: 2001-10-11
Abstract: The present invention provides novel compounds of the formula I and II for the treatment of non-insulin dependent diabetes mellitius (NIDDM) and a new use of known compounds for this purpose.
Patent DE-69616056-D1 (DE)
Inventor: RINALDI MURIELLE
IPC: C07D209/08
Filed: 1996-06-20
Granted: 2001-11-22
Abstract: The use of human CB2 receptor-specific agonists of formula (I) or (I') for preparing immunomodulating drugs is disclosed. In formulae (I) and (I'), R1 is a group selected from -CH2CHR10NR6R11, -(CH2)2NR'6R'11, -CHR9CH2NR'6R'11, -(CH2)nZ and -COR8; R'1 is a -CH2CHR10NR6R11 or -(CH2)2NR'6R'11 group; R2 and R'2 are hydrogen, halogen or C1-4 alkyl; R3 is hydrogen, C1-4 alkyl or a group selected from -CH2CHR10NR6R11, -(CH2)2NR'6R'11 and -COR8; R'3 is a =CR6R8 group; R4 has one of the meanings given for R5 or is a -COR8 group; R5 is hydrogen, C1-4 alkyl, C1-4 alkoxy, a halogen atom, a CF3 group, an OCF3 group or C1-4 alkylthio; R'5 has one of the meanings given for R5 and is in the 5 or 6 position of the indene ring; R6 is hydrogen or C1-4 alkyl; R'6 is C1-4 alkyl; R7 has one of the meanings given for R5 or R7 and R9 together form a -Y-CH2- group attached to the indole ring in the 7 position by a group Y; R8 is phenyl substituted one to four times by a substituent selected from halogen, C1-4 alkyl or C1-4 alkoxy; a polycyclic ring selected from naphth-1-yl, naphth-2-yl, 1,2,3,4-tetrahydronaphth-1-yl, 1,2,3,4-tetrahydronaphth-5-yl, anthryl, benzofuryl, benzothien-2-yl, benzothien-3-yl, 2-, 3-, 4- or 8-quinolyl, said polycyclic rings optionally being substituted once or twice by a substituent selected from C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, halogen, cyano, hydroxyl, trifluoromethyl and imidazol-1-yl; R10 and R11 together are a group selected from -CH2-O-CH2-CR12R13- and -(CH2)p-CR12R13-, wherein the carbon atom substituted by R12 and R13 is attached to the nitrogen atom; R'11 is C1-4 alkyl; or R'11 and R'6, taken together with the nitrogen atom to which they are attached, form a group selected from morpholin-4-yl, thiomorpholin-4-yl, piperidin-1-yl and pyrrolidin-1-yl; each of R12 and R13 is independently hydrogen or C1-4 alkyl; n is 2, 3, 4 or 5; p is 2 or 3; Z is a methyl group or a halogen atom; and Y is a methylene group or an oxygen atom.
Patent DE-69616988-D1 (DE)
Inventor: RHODES KEITH DANIEL
IPC: G06F19/00
Filed: 1996-01-17
Granted: 2001-12-20
Abstract: A computerized pharmaceutical care cognitive services mangement system and method (PC-CSMS) (24) allows the transformation of a pharmacist from a vendor to a health care provider. The PC-CSMS (24) captures all of the value added by a pharmacist to a patient encounter and permits the association of multiple RARs (Reason, Action, Result) (34) with a single SOAP (Subjective Information, Objective Information, Assessment, Plan) (32). The PC-CSMS (24) enables the pharmacist to be compensated for each analytical or counseling session (30) and/or service provided to the user associated with a single transaction. The PC-CSMS (24) also enables efficient processing of interruptions (36) to cognitive (28) and counseling (30) sessions. Upon reception of an interrupt (36) from a person or a telephone, the PC-CSMS (24) suspends the cognitive (28) or counseling (30) session for a first patient, processes the interrupt for the second patient and then resumes processing for the first patient.
Patent DE-69623647-D1 (DE)
Title: Polyurethane aus polysiloxan-polyol-makromeren
Inventor: LOHMANN DIETER
IPC: G02C7/04
Filed: 1996-12-10
Granted: 2002-10-17
Abstract: The present invention describes a polymer and a precursor thereof; a prepolymer made essentially from a macromer that is cross-linked, for example, via its free hydroxy groups with a polyisocyanate, the macromer being made essentially from a polysiloxane and a polyol component; processes for the production of such prepolymers and polymers; the use of such polymers, for example, as artificial corneas, as molded articles, especially as contact lens material; also the use of a prepolymer or polymer for coating surfaces, especially functionalized polymer surfaces.
Patent DE-69628126-D1 (DE)
Inventor: NGUYEN T
IPC: B41M1/08
Filed: 1996-06-21
Granted: 2003-06-18
Abstract: Lithographic plate compositions and a method for their production have been discovered that are especially useful in conjunction with digitally controlled lasers to directly construct printable images on lithographic plates. The plates comprise a substrate and an ablatable polymeric coating on the substrate where the ablatable, imageable coating is prepared by in situ or solution polymerization of conjugated monomers deposited on the plate by vapor deposition or in solution. Examples of such monomers are thiophene, pyrrole and aniline.
Patent DE-69637771-D1 (DE)
Inventor: DE VROOM ERIK
IPC: C12N11/02
Filed: 1996-07-16
Granted: 2009-01-22
Abstract: A new immobilized Penicillin G acylase with a surprisingly good performance has been provided for. By applying this new immobilized enzyme,  beta -lactam derivatives are prepared in high yield by enzymatic reaction of a parent amino  beta -lactam and a corresponding acylating agent.
Patent DE-69638298-D1 (DE)
Inventor: ZHANG JIE
IPC: A61K31/216
Filed: 1996-07-26
Granted: 2011-01-13
Abstract: An apparatus, product formulation, and method for improved dermal permeation of pharmaceuticals wherein the apparatus includes a thin drug formulation reservoir and a heat-generating chamber separated by a first non-permeable wall, wherein the reservoir and chamber are formed in or supported by a housing. The drug formulation reservoir houses or is capable of housing a predetermined amount of a formulation containing pharmaceutically-active agent(s). The heat-generating/temperature-regulating chamber includes a medium for generating controlled heat, preferably a chemical composition made of carbon, iron, water and/or salt which is activated upon contact with air (oxygen). The function of the heat-gencrating,/tcmpcrature-rcgulating clement is to heat the user's skin, rapidly bring the skin temperature to a desired and elevated narrow range and keep it in this range for sufficient time to obtain more rapid, enhanced and less variable dermal absorption of selected pharmaceutically-active agents and to obtain improved clinical effects. Structure for controlling the generation of heat is also disclosed. The apparatus may optionally include a spacing or standoff structure which spans the drug formulation reservoir between the non-permeable wall and the user's skin surface for maintaining a predetermined thickness of the drug formulation on the user's skin surface. Also, a novel product formulation which can be used with the apparatus which uses high percentage of eutectic mixture of local anesthetics to reduce the overall degradation rate of the local anesthetic compound(s) in formulations which are subject to hydrolysis.
Patent DE-69700629-D1 (DE)
Inventor: COMBES PATRICE
IPC: B21D35/00
Filed: 1997-01-08
Granted: 1999-11-25
Abstract: The method is used especially for making wiper blade carriers with deflector strips. The method involves subjecting a metal sheet to punching, cutting, folding, bending and other operations to form a series of parallel carrier sections (1) which are joined to the edges (9) of the sheet by bridges (8). Pins (6) are then attached to holes (15) designed for fitting the deflector strips while the carrier sections are still flat. After attaching the pins the carrier sections are folded and bent to the required shape, and are painted while still joined to the sheet edges.
Patent DE-69719994-D1 (DE)
Inventor: WEI HUACHEN
IPC: A61K8/29
Filed: 1997-06-09
Granted: 2003-04-24
Abstract: A method of inhibiting the harmful effect of UVR exposure to the human skin comprising topically applying a therapeutically effective amount of genistein to the skin at a time sufficiently close to the time of UVR exposure to inhibit UVR-induced damage to the skin. The genistein appears to act as a chemo preventative agent since it has no appreciable sun blocking effect. The genistein may be mixed with a variety of carriers and skin treatment compositions.
Patent DE-69734595-D1 (DE)
Inventor: HIROSE MINORU
IPC: C12Q1/6886
Filed: 1997-06-27
Granted: 2005-12-15
Abstract: A method for the detection of telomerase activity, for the detection of cancer cells and for the diagnosis of cancer comprising amplifying an oligonucleotide sequence extended by a DNA extension reaction with a telomerase and hybridizing the resulting amplified product with a probe labelled with a non-radioactive material to detect the telomerase activity, as well as a diagnositic kit for use in said method for the detection and diagnosis. <IMAGE>
Patent DE-69810541-D1 (DE)
Inventor: CHEVALET DIDIER
IPC: G09F15/00
Filed: 1998-07-07
Granted: 2003-02-13
Abstract: The frame (1) is made in two sections (2d,2g) which can pivot about a central vertical axis so they can occupy two different positions, one at an angle to one another for fitting the fabric layer and a second in a straight line for stretching it. The fabric is in the form of a cover with end pouches (91,92) to engage with the frame sections when they are set at an angle to one another, each frame section having a curved member (27) at its end to give the fabric cover a predetermined shape when stretched. The frame sections also have locking members to retain them in the deployed position and can incorporate light or sound systems.
Patent DE-69816874-D1 (DE)
Inventor: ANDERSSON GERT
IPC: B61G5/00
Filed: 1998-05-13
Granted: 2003-09-04
Abstract: A mass transit apparatus for an endless travelling path is known, consisting of consecutive vehicles, which are articulately connected in an endless configuration so that said vehicles can be folded to a side by side position from a linear position. In order to improve the speed reduction or acceleration ratio said vehicles connected to each other by means of distance beams (10) are pivotably connected to said vehicles (1) at points located at both end parts of said vehicles. Horizontal steering means (4, 15) are arranged to cause said vehicles to pivot horizontally from said linear position to said side by side position and in reverse along certain parts of said endless travelling path.
Patent DE-69831690-D1 (DE)
Inventor: FURUYA SHUICHI
IPC: A61K31/506
Filed: 1998-12-24
Granted: 2006-02-02
Abstract: A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R<SUP>1</SUP>, R<SUP>2 </SUP>and R<SUP>3 </SUP>each is (i) H or (ii) a group bound via C, N, O or S; R<SUP>4 </SUP>is a group bound via C; R<SUP>5 </SUP>is H or a group bound via C or O; R<SUP>6 </SUP>is H or a group bound via C; R<SUP>7 </SUP>is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.
Patent DE-69837760-D1 (DE)
Inventor: BLANK GREGORY S
IPC: C12P21/08
Filed: 1998-06-12
Granted: 2007-06-21
Abstract: The invention herein provides a method for recovering a polypeptide comprising exposing a composition comprising a polypeptide to a reagent which binds to, or modifies, the polypeptide, wherein the reagent is immobilized on a solid phase; and then passing the composition through a filter bearing a charge which is opposite to the charge of the reagent in the composition, so as to remove leached reagent from the composition.
Patent DE-69839368-D1 (DE)
Inventor: PASSI SIRO
IPC: A23L33/15
Filed: 1998-02-02
Granted: 2008-05-29
Abstract: The present invention relates to a dietary product comprising ubiquinone, stabilized vitamin E, phospholipids, selenuim in an organic form and L-methionin, which is effective to combat cell oxidative stress even to the extreme consequences thereof, for example cell decay, acquired and/or congenital immunodeficiency or other alterations in the immune system. The dietary product object of the present invention is also effective as a coadjutant in the treatment of apoptosis, in mutagenesis and/or carcinogenesis, in infectious diseases of viral or bacterial origin or those deriving from other external pathogens, in myelinic and skin diseases, in cardiovascular diseases and in allergies.